Skip to main content

Search
Profile

Michael C V Jensen, MD

|
Michael C V Jensen, MD

Children's Title: Director, Ben Towne Center for Childhood Cancer Research; Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research in honor of Korey Rose

Academic Title: Professor

Research Center: Ben Towne Center for Childhood Cancer Research

Making a Difference

  • Spearheading New Cancer Therapy

    Seattle Children’s takes a step toward revolutionizing the way cancer is treated with the hospital’s first reprogrammed T cell immunotherapy trial for relapsed leukemia. ... cont.

  • Families Fuel Discovery

    Many rare and devastating diseases lack effective treatments or cures. The faith, funds and passion of families of our patients jump-start the search for answers that will help seriously ill children lead healthier lives.... cont.

Recommendations

NathanLynnwood, Washington07.24.13
Dr. Jensen was in his Fellowship at Seattle Children's in 1994-1995 and was instrumental in my battle with Non-Hogkins. It was a scary time, but his ability to explain the processes, side-affects, and outlook was confident and caring for my parents and myself. As a patient and a child, I wanted to know what was going on and why. Dr. Jensen took the time to converse candidly with me about the cancer, the treatments, and the schedule. I think these conversations helped me to not fear the cancer or the treatments, that the only thing to fear is what I do not know. Dr. Jensen and the team at Seattle Children's have a beautiful vision and I have hope and confidence they will make it happen. Contrary to what I was told were possibilities: The salt in the pepperoni sticks that were the only thing I wanted to eat during treatment, didn't hurt me. The sun might have been bad for the skin because of the treatments, but it was great for my spirit (my Dermatologist does agree that I should stay away from it though). The infertility rate of childhood cancer survivors went down about 6 years ago when my wife Kristy and I welcomed our son, Jonathan. We also have a daughter, Kaleah (16 months). I closed my account at "the bank" after finding out I didn't need what was deposited. I would encourage anyone who was treated for childhood cancer by any doctor or hospital to participate in a "Long Term Follow-Up" study. Doing so creates a wealth of knowledge and helps communicate the need for Doctor Jensen's research. These studies document the impact of childhood cancer and treatments on survivors and their quality of life. Thank You Dr. Jensen for your continued care in the battle, Nathan Schauermann Survivor, Non-Hogkins T-cell Lymphoma
LaceyLos Angeles, CA12.02.11
Dr. Jensen was my pediatric oncologist at a California hospital before he moved to Seattle Children's; and before I met him I was given a 30% chance to live. That was 12 years ago. To Dr. Jensen you are more than just a chart, number, or disease, you are a human being. His bedside manner, I have yet to see duplicated, and when he told me I was cancer free and would no longer need treatments, I cried, because I was going to miss HIM. I'm happy to say that I am doing well and I'm getting ready to celebrate my 25th birthday, a birthday I likely would not have had if not for Dr. Jensen. Thank you doctor for everything you have done for pediatric cancer patients everywhere, and for giving me my life back!
Recommend Dr. Michael Jensen

Overview

Medical/Professional School
University of Pennsylvania School of Medicine, Philadelphia
Residency
Pediatrics, Children's Hospital of Northern California, Oakland
Fellowship
Pediatric Hematology-Oncology, University of Washington, Seattle
Lab URL

http://www.seattlechildrens.org/research/childhood-cancer/our-science/our-labs/jensen-lab

Research Focus Area

Cancer

Publications

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Immunological reviews , 2014 Jan: 257(1)127-44
Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma.
PloS one , 2013 Dec 17: 8(12)e82742
Chimeric c cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
Molecular immunology , 2013 Nov: 56(1-2)1-11
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Blood , 2013 Oct 31: 122(18)3138-48
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2013 Jun 15: 19(12)3153-64
Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.
PloS one , 2013: 8(6)e65519
Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2013 Jan: 19(1 Suppl)S2-5
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Journal of immunotherapy (Hagerstown, Md. : 1997) , 2012 Nov-Dec: 35(9)689-701
Engineered T cells for anti-cancer therapy.
Current opinion in immunology , 2012 Oct: 24(5)633-9
Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Molecular immunology , 2012 Jul: 51(3-4)263-72
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood , 2012 Apr 26: 119(17)3940-50
Stem-like tumor-initiating cells isolated from IL13R2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2012 Apr 15: 18(8)2199-209
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
Blood , 2012 Jan 5: 119(1)72-82
Cytotoxic T lymphocyte trafficking and survival in an augmented fibrin matrix carrier.
PloS one , 2012: 7(4)e34652
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.
Blood , 2011 Aug 4: 118(5)1255-63
Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.
Blood , 2011 Feb 10: 117(6)1888-98
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Blood , 2010 Nov 25: 116(22)4532-41
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2010 Sep: 16(9)1245-56
Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2010 Jul 1: 16(13)3399-408
Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis.
Cytometry. Part A : the journal of the International Society for Analytical Cytology , 2010 Jun: 77(6)534-45
Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems.
Proceedings of the National Academy of Sciences of the United States of America , 2010 May 11: 107(19)8531-6
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
Journal of immunology (Baltimore, Md. : 1950) , 2010 Apr 15: 184(8)4284-94
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
Blood , 2009 Dec 24: 114(27)5454-63
Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
Cancer research , 2009 Dec 1: 69(23)8886-93
Safety and immunologic effects of IL-15 administration in nonhuman primates.
Blood , 2009 Sep 17: 114(12)2417-26
Adoptive transfer of virus-specific and tumor-specific T cell immunity.
Current opinion in immunology , 2009 Apr: 21(2)224-32
Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma.
Nature clinical practice. Oncology , 2009 Jan: 6(1)53-8
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Blood , 2008 Sep 15: 112(6)2261-71
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2008 Jun 15: 14(12)3832-9
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
Journal of immunology (Baltimore, Md. : 1950) , 2008 May 15: 180(10)7028-38
Engineering GVL through T cell gene transfer.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2008 Jan: 14(1 Suppl 1)5
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
The Journal of clinical investigation , 2008 Jan: 118(1)294-305
Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Journal of pediatric hematology/oncology , 2007 Oct: 29(10)669-77
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
Journal of immunology (Baltimore, Md. : 1950) , 2007 Sep 1: 179(5)3332-41
Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
Journal of immunotherapy (Hagerstown, Md. : 1997) , 2007 Sep: 30(6)644-54
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
Experimental hematology , 2007 Jul: 35(7)1083-90
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
Molecular therapy : the journal of the American Society of Gene Therapy , 2007 Apr: 15(4)825-33
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
Cancer research , 2007 Mar 15: 67(6)2872-80
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
Nature medicine , 2007 Jan: 13(1)84-8
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Cancer research , 2006 Nov 15: 66(22)10995-1004
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
Blood , 2006 Apr 1: 107(7)2643-52
In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma.
Molecular imaging , 2006 Apr-Jun: 5(2)57-64
A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells.
Journal of immunological methods , 2005 Jul: 302(1-2)78-89
Amplification of RNAi--targeting HLA mRNAs.
Molecular therapy : the journal of the American Society of Gene Therapy , 2005 May: 11(5)811-8
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
Blood , 2005 Feb 15: 105(4)1622-31
Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.
Journal of immunological methods , 2005 Feb: 297(1-2)39-52
T-cell genetic modification for re-directed tumor recognition.
Cancer chemotherapy and biological response modifiers , 2005: 22293-324
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Cancer research , 2004 Dec 15: 64(24)9160-6
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
Blood cells, molecules & diseases , 2004 Jul-Aug: 33(1)83-9
Enhanced transgene expression in quiescent and activated human CD8+ T cells.
Human gene therapy , 2004 Jul: 15(7)648-58
Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
The journal of gene medicine , 2004 Jun: 6(6)704-11
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Molecular therapy : the journal of the American Society of Gene Therapy , 2004 Apr: 9(4)577-86
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.
The Journal of experimental medicine , 2003 Sep 15: 198(6)947-55
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
Blood , 2003 Feb 15: 101(4)1637-44

Primary Office

Seattle Children's
OL-1 - Ben Towne Center for Childhood Cancer Research
1100 Olive Way
Seattle, WA 98101
206-884-7900

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options